WallStSmart
LGVN

Longeveron LLC

NASDAQ: LGVN · HEALTHCARE · BIOTECHNOLOGY

$0.70
+5.26% today

Updated 2026-06-03

Market cap
$23.07M
P/E ratio
P/S ratio
18.97x
EPS (TTM)
$-1.14
Dividend yield
52W range
$0 – $2
Volume
0.6M

Longeveron LLC (LGVN) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-5.18M$-2.39M$-2.36M$-9.64M$-13.97M$-19.00M$-13.87M$-18.64M
Capital expenditures$211684.00$37573.00$261500.00$1.31M$856000.00$301000.00$992000.00$245000.00
Depreciation
Stock-based comp$423866.00$136846.00$83000.00$7.74M$2.17M$2.03M$2.33M$1.68M
Free cash flow$-5.39M$-2.43M$-2.63M$-10.95M$-14.82M$-19.30M$-14.86M$-18.89M
Investing cash flow
Financing cash flow
Dividends paid$451000.00$8.65M
Share repurchases
Debt repayment
Net change in cash$24.84M$-15.15M

Frequently asked questions

What is Longeveron LLC's revenue?

Longeveron LLC's trailing twelve-month revenue is $1.22M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is LGVN?

In its most recent fiscal year, LGVN ran a gross margin of 66.97%, an operating margin of -1,942.20%, and a net margin of -1,893.58%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does LGVN generate?

LGVN produced $-18.89M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LGVN's balance sheet healthy?

LGVN holds $4.66M in cash and equivalents against — in long-term debt, on $5.67M of shareholder equity. That debt is best read against the cash flow the business throws off each year.